From: Dendritic cell biology and its role in tumor immunotherapy
DC | Tumor type | Combination therapy | Route, dose | Comparison (Medication group and control group) | Efficacy (partial response, PR; complete response, CR; overall survival, OS; progression-free survival, PFS) | Safety (grade III and IV adverse events) | Phase (I, II, III, n) | Trial registration | Ref. |
---|---|---|---|---|---|---|---|---|---|
CMV pp65 RNA-loaded DCs | Glioblastoma | CMV pp65-specific T cells | Â | 17 patients were randomized to receive CMV pp65-specific T cells with CMV-DC vaccination or saline | Increased in polyfunctional CMV-specific CD8+ T cells, correlated with overall survival | Â | I (17) | NCT00693095 | [110] |
CMV pp65 mRNA pulsed DCs | Glioblastoma | DI-TMZ, GMCSF | DI-TMZ (100 mg/m2/d × 21 days per cycle), at least three DC vaccines, GM-CSF on day 23 ± 1 of each cycle. | Single arm | Median PFS and OS were 25.3 months and 41.1 months |  | I (11) | NCT00639639 | [111] |
hTERT-DCs | Acute myeloid leukemia |  | 1 × 107 cells, 6 weekly injections, 6 biweekly injections | Single arm | Median follow-up of 52 months, 58% of patients in CR |  | II (36) | NCT00510133 | [112] |
DCs electroporated with Wilms' tumor 1 (WT1) mRNA | Acute myeloid leukemia |  | Intradermal injection of 0.5 × 1e6 WT1/DCs on the back of the patient | Single arm: 30 patients with AML at very high risk of relapse | 5 year OS was higher in responders than in nonresponder patients. Age ≤ 65 and > 65, 5 year OS was 69.2% and 30.8% |  | II (30) | NCT00965224 | [113] |
HER2 peptide-pulsed DC1s | HERpos breast cancer | Â | Â | Patients were randomized for different injection routes | CR for ductal carcinoma in situ, invasive breast cancer patients was 28.6% and 8.3% | Well tolerated | I (54) | NCT02061332 | [114] |
Autologous tumor lysate plus DC | Metastatic colorectal cancer (mCRC) |  |  | 52 patients were randomized to DC + best supportive care (BSC) vs. BSC | Median OS was 6.2 months in DC+BSC versus 4.7 months in BSC |  | III (52) | NCT01413295 | [115] |
DCs pulsed with killed PCa cells | Prostate cancer | Chemotherapy | Metronomic cyclophosphamide 50 mg p.o., DCVAC/PCa 1 × 107 dendritic cells per dose injected | Single arm: progressive metastatic castration-resistant prostate cancer | The median OS was 19 months |  | I/II (25) | CT 2009-017295-24 | [116] |
Autologous DCs pulsed with allogeneic tumor cell lysate | Mesothelioma |  | First, second and third cohort received 10, 25, 50 million monocyte-derived DCs per vaccination | 9 patients divided over three different dose cohorts | Median PFS was 8.8 months | No dose limit | I (9) | NCT02395679 | [117] |
Autologous activated DCs | Lung cancer | Activated killer T cell AKT, chemoth., EGFR-TKI | Â | Group A, immunotherapy; group B, chemotherapy. | The 2- and 5-year OS rates were 96.0 and 69.4% in group A and 64.7 and 45.1% in group B | Â | III (103) | UMIN000007525 | [118] |
Activated DCs | Diverse solid tumors |  | Intratumorally injected at 2, 6, 15 million aDCs | Single arm | OS and TNFα levels increased |  | I (39) | NCT01882946 | [119] |
Tumor antigen-pulsed DCs | Hepatocellular carcinoma |  | Dendritic cell vaccines injected subcutaneously near to inguinal lymph nodes. | Single arm: patients with no viable tumor after primary treatments were included | 9 patients had no tumor recurrence up to 24 weeks | Primary treatment for HCC. | I/IIa (9) | KCT0000427 | [120] |
Peptide-pulsed DCs | Pancreatic cancer (PC) | Toll-like receptor (TLR)-3 agonist poly-ICLC | Peptide-pulsed DC vaccines every 2 weeks. Concurrent intramuscular administration of Poly-ICLC | Single arm: 9 patients with metastatic PC, and 3 patients with locally advanced unresectable PC | Median overall survival was 7.7 months. One patient survived for 28 months |  | I (11) | NCT01410968 | [121] |
mRNA Electroporated DCs | Advanced melanoma | TriMixDC-MEL plus ipilimumab | Intradermally and intravenously plus ipilimumab every 3 weeks, then every 12 weeks | Single arm | 6-month disease control rate was 51%, the overall tumor response rate was 38% |  | II (39) | NCT01302496 | [122] |
Ad-CCL21 Gene-Modified DCs | NSCLC | None | 2 vaccinations by intratumoral injections | Single arm: stage IIIB/IV NSCLC | 4/16 patients had stable disease at day 56. Median survival was 3.9 months |  | I (16) | NCT01574222 | [123] |
Autologous tumor lysate pulsed with DCs | Bone and soft tissue sarcoma | Â | 6 weekly DC injections into the inguinal or axillary region. | Single arm: metastatic or recurrent sarcomas | The 3-year overall and progression-free survival rates were 42.3% and 2.9% | Â | I/II (37) | Â | [124] |
Autologous tumor cell pulsed Dcs (VAX-DC/MM) | Multiple myeloma | Monocyte-derived immature DCs | Intradermal VAX-DC/MM injection of 10 × 1e6 cells every week for 4 weeks | Single arm: relapsed or refractory MM | Most patients (77.8%) who received 10 × 1e6 cells showed an immunological response |  | I (12) | NCT02248402 | [125] |
None | High-risk stage III/IV melanoma | GM-CSF, multiepitope melanoma peptide | Â | A multicenter intergroup randomized placebo-controlled trial | 11.3% vs. 27.1% patients developed peptide-specific CD8+ T cell responses. | Â | III (815) | NCT01989572 | [126] |